Analysts on Wall Street project that Danaher (DHR) will announce quarterly earnings of $1.92 per share in its forthcoming report, representing an increase of 1.6% year over year. Revenues are projected to reach $6.55 billion, increasing 8.2% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Given this perspective, it's time to examine the average forecasts of specific Danaher metrics that are routinely monitored and predicted by Wall Street analysts.
The consensus among analysts is that 'Total Sales- Diagnostics' will reach $2.83 billion. The estimate points to a change of +14.9% from the year-ago quarter.
Analysts' assessment points toward 'Total Sales- Life Sciences' reaching $1.84 billion. The estimate indicates a change of +2.9% from the prior-year quarter.
Analysts forecast 'Total Sales- Biotechnology' to reach $1.87 billion. The estimate indicates a year-over-year change of +4%.
According to the collective judgment of analysts, 'Total Growth - Organic sales (Core)' should come in at 2.5%. Compared to the present estimate, the company reported 3.0% in the same quarter last year.
Analysts predict that the 'Operating profit- Life Sciences' will reach $255.41 million. The estimate compares to the year-ago value of $222.00 million.
Analysts expect 'Operating profit- Biotechnology' to come in at $483.60 million. The estimate is in contrast to the year-ago figure of $352.00 million.
The average prediction of analysts places 'Operating profit- Diagnostics' at $704.10 million. The estimate is in contrast to the year-ago figure of $665.00 million.
View all Key Company Metrics for Danaher here>>>Over the past month, Danaher shares have recorded returns of +8.9% versus the Zacks S&P 500 composite's +2.4% change. Based on its Zacks Rank #2 (Buy), DHR will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Danaher Corporation (DHR): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).